ArticleDiagnostics (Basel, Switzerland)2024

Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma.

Jolita Palacionyte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.